Japanese Pharma Companies Turning to CDMOs Earlier in Product Life Cycle
The bottleneck isn’t discovery anymore. It’s execution. In peptides, programs are running into challenges around analytical complexity, scaleup, and the availability of key raw materials such as protected amino acids. The post Japanese Pharma Companies Turning to CDMOs Earlier in Product Life Cycle appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.